+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy



Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy



American Journal of Hematology 90(9): E181-E182




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058153218

Download citation: RISBibTeXText

PMID: 26119985

DOI: 10.1002/ajh.24033


Related references

Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy. Leukemia and Lymphoma 45(3): 469-480, 2004

CNS relapse in a low risk acute promyelocytic leukemia patient treated with ATRA-based regimen: is there a role for prophylactic CNS therapy in acute promyelocytic leukemia?. Indian Journal of Hematology and Blood Transfusion 25(3): 118-119, 2009

Central nervous system involvement at second relapse in acute promyelocytic leukemia treated with ATRA and chemotherapy. Leukemia Research 34(10): E264-E265, 2010

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leukemia and Lymphoma 60(5): 1146-1155, 2019

Double extramedullary relapse in acute promyelocytic leukemia following treatment with ATRA and chemotherapy. Blood 88(10 Suppl. 1 Part 1-2): 169B, 1996

Long term follow-up of 24 patients with acute promyelocytic leukemia treated with ATRA and consolidation chemotherapy. Blood 84(10 Suppl. 1): 619A, 1994

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Annals of Hematology 97(10): 1797-1802, 2018

Sustained remission achieved with ATRA and chemotherapy in second relapse of acute promyelocytic leukemia in Down syndrome. Journal of Pediatric Hematology/Oncology 31(8): 539-540, 2009

Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia and Lymphoma 59(5): 1268-1270, 2018

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94(4): 1192-1200, 1999

The results of long-term follow-up of acute promyelocytic leukemia treated with ATRA in combination with chemotherapy. Leukemia 8(6): 1089, 1994

All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1 -mutated AML unfit for intensive chemotherapy and review of the literature. Clinical Case Reports 4(12): 1138-1146, 2016

Outcome of acute promyelocytic leukemia (APL) with very high WBC counts treated with ATRA and chemotherapy (CT): The European group experience. 2007

Acute promyelocytic leukemia: All-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone. American Journal of Hematology 60(2): 87-93, 1999

Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. Annals of Hematology 96(9): 1449-1456, 2017